Cytokinetics has announced that a Phase II trial of ispinesib for head and neck cancer failed to hits its primary endpoint. The best overall response trial was disease stabilization, which was observed in 5 of the 19 patients. In a press release, the company said the results didn't justify moving ispinesip on to further trials. Back in March Cytokinetics determined that inpinesib didn't demonstrate sufficient anti-tumor activity to justify moving on to the next step in a mid-stage study. Cytokinetics is developing the drug with GlaxoSmithKline.
- see the company press release